先进的糖化最终产品:长期暴露于血糖的标志物
David C Klonoff1, Rachel E Aaron2, Tiffany Tian2
1Diabetes Research Institute, Mills-Peninsula Medical Center, San Mateo, CA, USA.
Journal of diabetes science and technology
|March 25, 2024
概括
先进的糖化最终产品 (AGEs) 导致糖尿病并发症. 皮肤自光 (SAF) 可以测量AGE,识别血管疾病和糖尿病并发症高风险的个体.
科学领域:
- 生物化学 生化学
- 内分泌学 在内分泌学.
- 血管生物学 血管生物学
背景情况:
- 先进的糖化最终产品 (AGEs) 与病理变化有关.
- AGEs有助于代谢记忆,并预测糖尿病并发症.
- 某些人群,如黑人和西班牙裔/拉丁裔美国人,显示HbA1c高于预期.
研究的目的:
- 检查AGE在糖尿病并发症和心血管疾病中的作用.
- 评估皮肤自发光 (SAF) 作为估计AGE负担的方法.
- 探索AGE作为糖尿病人和非糖尿病人的风险预测因素.
主要方法:
- 关于AGE结构和病理学的文献综述.
- 皮肤自发光 (SAF) 的检查,以测量AGE.
- 对AGE对代谢记忆和并发症的贡献的分析.
主要成果:
- AGEs与糖尿病并发症和心血管疾病有关.
- SAF是一种用于估计AGE负担的实用方法.
- 增高的AGE可能会解释某些人群中并发症率的增加.
结论:
- 现有证据支持SAF作为评估AGE负担的临床测量.
- SAF可以评估旨在减少血管疾病和糖尿病并发症风险的干预措施.
- 通过SAF测量AGE可以识别高风险个人进行主动管理.
相关概念视频
Diabetes: Symptoms, Diagnosis, and Complications
530
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
530
Diabetes Mellitus: Type 2 and Gestational
2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K
Hypoglycemia and Glucagon
257
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
257
Proteoglycans
3.9K
Glycans, a class of complex heterogeneous molecules, can be covalently attached to proteins to form glycosylated proteins that regulate various physiological and pathological processes. Glycosylated proteins or glycoproteins comprise N-linked and O-linked oligosaccharides. O-glycosylation is the most common type of protein glycosylation. Here, glycans attach to the oxygen atom of the hydroxyl groups of Serine or Threonine residues. O-linked glycosylation occurs later in protein processing,...
3.9K
Pathophysiology of Diabetes
926
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
926
Glucagon-like Receptor Agonists
321
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
321


